Illegally copied medicinal products, which apparently contain the active substance rimonabant, are sold at several websites.
Rimonabant has been developed for treatment of obesity, but it has not yet been authorised for sale. The quality, safety and effect of the product are currently being evaluated by the European Medicines Agency (EMEA).
The company that has developed rimonabant is planning to sell it under the trade name Acomplia if EMEA decides to authorise the product.
The Danish Medicines Agency encourages people who have bought the medicinal product to stop using it and to hand the rest of the product over to a pharmacy.
For further information, please contact Christina Palvad, telephone +45 4488 9731.